Table 4. The effect of genotype on the... | American Society of Hematology

Table 4.

The effect of genotype on the relative risk (95% confidence interval) for the primary end point, myocardial infarction, and bleeding in Pl^A2 carriers according to treatment

Event	Placebo	Orbofiban
Primary endpoint^4-150	0.87 (0.49, 1.55)	1.55 (1.03, 2.34)^‡
Myocardial infarction^4-150	1.04 (0.28, 3.92)	4.27 (1.82, 10.03)^4-153
Bleeding^4-151	1.22 (0.67, 2.22)	0.59 (0.39, 0.92)^‡

Event	Placebo	Orbofiban
Primary endpoint^4-150	0.87 (0.49, 1.55)	1.55 (1.03, 2.34)^‡
Myocardial infarction^4-150	1.04 (0.28, 3.92)	4.27 (1.82, 10.03)^4-153
Bleeding^4-151	1.22 (0.67, 2.22)	0.59 (0.39, 0.92)^‡

Risks are relative to Pl^A2 noncarriers.

F4-150

Results of a proportional hazards analysis adjusted for age and sex.

F4-151

Results of a proportional hazards analysis adjusted for age, sex, and country.

‡

P < .05.

F4-153

P < .001.

View Large

This Feature Is Available To Subscribers Only